热门资讯> 正文
麦基森在季度业绩下滑后上调26财年每股收益预期
2026-02-05 05:58
- McKesson (MCK) boosted its fiscal 2026 non-GAAP EPS outlook as the drug wholesaler's Q3 financial results beat on both lines.
- The company now sees FY26 non-GAAP EPS of $38.80-$39.20, up from $38.35-$38.85 prior. Consensus is $38.68.
- In Q3, non-GAAP EPS rose to $9.34 from $8.03 in the year-ago period, a 16% increase.
- McKesson said Q3 results were helped by growth in the North American Pharmaceutical segment following increased prescription volumes from retail national account customers and distribution growth of oncology and multispecialty products.
- McKesson ended 2025 with ~$3B in cash and cash equivalents compared to ~$5.7B on March 31, 2025.
More on McKesson
- 44th Annual J.P. Morgan Healthcare Conference
- McKesson Corporation (MCK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- McKesson Corporation: FY26 Earnings Visibility Underpins Buy Case
- McKesson Non-GAAP EPS of $9.34 beats by $0.07, revenue of $106.2B beats by $290M
- McKesson Q3 2026 Earnings Preview
推荐文章
华尔街大多头漫谈黄金“黑天鹅”风险：马斯克实现太空采金，化身全球央行行长
避险情绪席卷市场 华尔街青睐的热门交易纷纷崩跌
华盛早报 | 无一幸免！美股、金银、加密货币与原油集体崩盘；南向资金爆买250亿港元！创约半年来新高；千问APP今日启动30亿免单
亚马逊股价盘后大跌近10%，巨额资本支出引发担忧
比特币暴跌带来124亿美元巨亏 Saylor的金融实验岌岌可危
2月6日外盘头条：比特币暴跌 亚马逊预计今年资本支出将达2000亿美元 交易员料美联储将比预期更早降息
美股机会日报 | “恐慌指数”飙升！美国1月计划裁员数激增，纳指期货跌近1%；谷歌绩后大跌近5%
“AI恐慌”引软件股集体回调超20%！哪类公司被错杀了？
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
